文献速递真实世界研究与卫生经济流行病学与生物统计

多中心临床试验结果能否改变临床实践?长效注射利培酮在美国退伍军人健康管理局全国范围内的使用情况

Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration.
PubMed 文献 · Trials · 2023-02-06

该研究利用美国退伍军人健康管理局(VHA)国家行政数据,分析2011年发表的多中心随机对照试验CSP#555(比较长效注射利培酮与口服抗精神病药,疗效与成本效果均为阴性)发表前后各4年长效注射利培酮新起始使用情况。结果显示,研究发表后长效注射利培酮新起始人数和比例显著下降,但下降趋势在发表前已出现,可能与更长效的帕利哌酮长效注射剂上市有关。

要点

  • CSP#555试验发表后,长效注射利培酮新起始人数和比例显著下降。
  • 新起始下降趋势在CSP#555发表前(2007-2010年)即已出现。
  • 下降可能主要反映更长效的帕利哌酮长效注射剂替代,阴性结果可能强化该趋势。

核心结论

  • 长效注射利培酮使用下降可能主要反映研究发表前2年上市的长效注射帕利哌酮的替代,CSP#555的阴性结果可能强化了这一替代。

研究设计与样本

  • 纵向观察性分析,利用VHA国家行政数据,比较CSP#555于2011年发表前后各4年长效注射利培酮新起始使用情况。
  • 纳入2007年至2015年诊断为精神分裂症或分裂情感性障碍并接受抗精神病药治疗的119,565名退伍军人。

主要发现

  • 研究发表后,长效注射利培酮新起始人数和比例显著下降,年使用总人数和药品支出也下降。
  • 2007年至2010年数据显示,新起始下降实际早于CSP#555发表。
  • CSP#555发表前2年,较长效注射利培酮作用更长的长效注射帕利哌酮(4周剂型)的新起始、总使用和支出增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multisite practical clinical trials evaluate treatments in real-world practice. A multisite randomized Veterans Health Administration (VHA) cooperative study (CSP#555) published in 2011 compared the first long-acting injectable (LAI) second-generation antipsychotic (SGA), Risperidone Consta®, in veterans with a diagnosis of schizophrenia or schizoaffective disorder, to oral antipsychotics, with unexpected null results for effectiveness and cost-effectiveness. Whether null results of this type could change VHA practice has not been studied. METHODS: A longitudinal observational analysis was used to evaluate the impact of the trial findings on VHA clinical practices. National administrative data compared new starts on LAI risperidone during the 4 years before the publication of CSP#555 in 2011 to new starts on LAI risperidone during the 4 years after. RESULTS: Among 119,565 Veterans with the indicated diagnoses treated with antipsychotics from 2007 to 2015, the number and proportion of new starts on LAI risperidone declined significantly following the study publication, as did the total number of annual users and drug expenditures. However, data from 2007 to 2010 showed the decline in new starts actually preceded the publication of CSP#555. This change was likely explained by the increase in new starts, total use, and expenditures on a newer medicine, LAI paliperidone, a 4-week LAI treatment, in the 2 years prior to the publication of CSP#555. CONCLUSIONS: The declining use of LAI risperidone likely primarily reflects the substitution of a longer-acting LAI SGA, paliperidone, that came to market 2 years before the study publication, a substitution that may have been reinforced by null CSP#555 study results for LAI risperidone.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rosenheck R, Anand ST, Kurtz SG, et al. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. Trials. 2023. PMID: 36747254. doi:10.1186/s13063-023-07094-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。